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B7-1 and B7-2 Have Overlapping, Critical Roles
in Immunoglobulin Class Switching
and Germinal Center Formation
Frank Borriello,*² Michael P. Sethna,* Scott D. Boyd,* suppress autoimmunity in rodents (Cross et al., 1995;
Finck et al., 1994; Perrin et al., 1995). These findingsA. Nicola Schweitzer,* Elizabeth A. Tivol,*
have inspired great interest inmanipulating this pathwayDouglas Jacoby,* Terry B. Strom,³
for therapeutic purposes. Methods for regulating thisElizabeth M. Simpson,§# Gordon J. Freeman,‖#
pathway are providing new strategies for achievingand Arlene H. Sharpe*
transplantation tolerance, controlling allergies and auto-*Immunology Research Division
immune diseases, and inducing immunity to infectiousDepartment of Pathology
agents and tumors. However, the presence of multiple²Division of Rheumatology/Immunology
ligands, B7-1 (CD80) (Freeman et al., 1989, 1991; Freed-Department of Medicine
man et al., 1987; Yokochi et al., 1982) and B7-2 (CD86)Brigham and Women's Hospital
(Freeman et al., 1993a, 1993b, 1993c; Azuma et al.,and Harvard Medical School
1993), and receptors, CD28 (June et al., 1994; LinsleyBoston, Massachusetts 02115
et al., 1990) and CTLA-4 (CD152) (Harper et al., 1991),³Department of Medicine
together with the potential for both positive and negativeDivision of Immunology
signaling (Walunas et al., 1994; Gribben et al., 1994;Beth Israel Hospital
Waterhouse et al., 1995; Tivol et al., 1995; Krummeland Harvard Medical School
and Allison, 1995), indicates that additional insights areBoston, Massachusetts 02115
needed to manipulate this key immunoregulatory path-§The Jackson Laboratory
way optimally.Bar Harbor, Maine 04609
The discovery of B7-2 (Freeman et al., 1993b, 1993c;‖Division of Hematologic Malignancies
Azuma et al., 1993) provided the impetus for a compara-Department of Medicine
tive analysis of B7-1 and B7-2 to determine the func-Dana±Farber Cancer Institute
tional necessity for two CD28/CTLA-4 counterreceptors.and Harvard Medical School
Although B7-1 and B7-2 show only modest (25%) aminoBoston, Massachusetts 02115
acid conservation, both are members of the immuno-
globulin supergene family and have similar low affinities
for CD28 and high affinities for CTLA-4 (Freeman et al.,Summary
1993b). However, they have distinct kinetics of binding
to CD28 and CTLA-4, with B7-2 having faster dissocia-Humoral immune responses were characterized in
tion kinetics, and utilize different binding determinantsmouse strains lacking either or both B7 molecules.
(Linsley et al., 1994), suggesting a means by which B7-1Mice deficient in both B7-1 and B7-2 failed to generate
and B7-2 could lead to distinct signals. While both B7-1antigen-specific IgG1 and IgG2a responses and lacked
and B7-2 display a very restricted pattern of expressiongerminal centers when immunized by a number of
on antigen-presenting cells (APCs), B7-1 and B7-2 areroutes and even in the presence of complete Freund's
differentially expressed. Most APCs require stimuli foradjuvant. Theseresults demonstrate thatB7-mediated
the induction of B7-1 and B7-2 expression (Lenschowsignaling plays a critical role in germinal center forma-
et al., 1994; Boussiotis et al., 1993) and, significantly,tion and immunoglobulin class switching in vivo. Mice
B7-2 is induced more rapidly than B7-1. Similar to B7-1,lacking only B7-1 or B7-2 mounted high-titer antigen-
B7-2 is highly expressed on activated B cells, while onlyspecific IgG responses when immunized in complete
low expression of B7-2 is detectable on resting B cellsFreund's adjuvant, indicating that B7-1 and B7-2 can
(Azuma et al., 1993; Hathcock et al., 1993). On restinghave overlapping, compensatory functions for IgG re-
monocytes, B7-2 is constitutively expressed (Azuma etsponses. When immunized intravenously without ad-
al., 1993), whereas B7-1 is inducible (Freedman et al.,juvant, B7-2-deficient mice failed to switch antibody
1991). B7-2 is constitutively expressed at moderate lev-isotypes or form germinal centers, whereas B7-1-defi-
els on dendritic cells, and both B7-1 and B7-2 can be
cient mice gave antibody responses comparable with
rapidly up-regulated on dendritic cells (Larsen et al.,wild-type mice. Thus, B7-2 has an important role
1994; Inaba et al., 1994). The constitutiveor early expres-in initiating antibody responses in the absence of
sion of B7-2 has led to the hypothesis that B7-2 mayadjuvant, but the induction of B7-1 by adjuvant in
be more important in initiating an immune response
B7-2-deficient mice can compensate for the absence
(Freeman et al., 1993b, 1993c), thereby playing a pivotal
of B7-2.
role in the decision between T cell activation and anergy,
whereas B7-1, being expressed later, may serve to am-
Introduction plify or regulate the immune response.
Whether B7-1 and B7-2 have identical, overlapping,
The importance of the B7-CD28/CTLA-4 pathway in vivo or distinct functions is underactive investigation. Recent
has been illustrated dramatically by studies indicating in vitro studies using monoclonal antibodies (MAbs) di-
that blockade of this pathway can induce long-term graft rected against B7-1 and B7-2 and with transfectants
survival (Lenschow et al., 1992; Turka et al., 1992) and expressing B7-1 or B7-2 have yielded conflicting results,
with some investigators finding unique functional out-
comes of costimulation by B7-1 and B7-2 (in particular,# These authors contributed equally to this work.
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Figure 1. Targeted Disruption of the B7-2
Gene
(A) Structure of the B7-2 targeting construct.
The neomycin resistance gene (neoR) is
flanked by z1.7 and z6.5 kb genomic DNA
fragments. The thymidine kinase gene (TK)
lies external to the 59 genomic DNA fragment.
The EcoRV and HindIII sites shown are the
sites used to generate the construct and to
analyze the integration sites. There are addi-
tional EcoRV and HindIII sites 39 of the neoR
gene in the construct.
(B) Wild-type allele. Intron-exon organization
of the IgV-like, IgC-like, and transmembrane
domains of B7-2 are depicted as rectangles.
The genomic probe used for subsequent
Southern blotting is indicated with a closed
bar and is located external to the genomic
DNA fragment used in the targeting con-
struct.
(C) Structure of the predicted targeted allele.
Gene targeting in ES cells by homologous
recombination results in the replacement of
the IgV domain contained in a 0.9 kb HindIII±
EcoRI fragment with the neomycin resistance
gene. Southern blot analysis uses the acqui-
sition of an additional EcoRV site upstream of one already present in the IgC-like domain to distinguish the targeted from the endogeneous
allele.
(D) Southern blot analysis of tail DNA from B7-2 knockout (2/2), heterozygote (1/2), and wild-type (1/1) littermates demonstrating the two
bands indicative of the endogenous (8.5 kb) and targeted (7.0 kb) configuration.
differences in interleukin-4 [IL-4] production [Freeman IgG2a response even in the presence of the potent com-
plete Freund's adjuvant (CFA). Taken together, theseet al., 1995] and CTL induction [Gajewski, 1996]) and
other investigators observing no differences (Lanier et studies demonstrate overlapping functions of B7-1 and
B7-2 and a critical role for B7-mediated signaling inal., 1995). In vivo blocking studies with anti-B7-1 and
B7-2 MAbs indicate that costimulation by B7-1 and B7-2 immunoglobulin class switching and germinal center
formation. The profound deficits in bothantigen-specificcan differentially influence the induction and course of
autoimmune disease in EAE (Perrin et al., 1995; Miller IgG1 (T helper type 2 [Th2]-dependent) and IgG2a (Th1-
dependent) responses demonstrate that B7 costimula-and Karpus, 1994; Lenschow et al., 1995) and NOD
(Lenschow et al., 1995) mouse models. tion can influence both Th1 and Th2 responses in vivo.
To evaluate the obligatory roles of B7-1 and B7-2 in
vivo, we generated mouse strains deficient (2/2) in B7-1 Results
(Freeman et al., 1993a), B7-2, or both B7-1 and B7-2
(B7-1/2 double deficient mice) by gene targeting in em- Generation of B7-2- and B7-1/2-Deficient Mice
We used gene targeting in ES cells tocreate mice lackingbryonic stem (ES) cells. Comparative analyses of mice
lacking either B7-1 or B7-2 or both B7 costimulatory B7-2 expression. Our targeting vector replaced the B7-2
IgV-like exon and adjacent intronic sequences with themolecules provide a means to ascertain unique, as well
as overlapping, functions for these two CD28/CTLA-4 neomycin drug resistance gene, which should result in
loss of all but the first 21 bp of the IgV-like domain exoncounterreceptors. Mice lacking expression of both B7-1
and B7-2 serve as a valuable tool for analyzing the con- and z0.5 kb of the downstream intron and effectively
destroy the functionally important IgV-like domain ofsequences of inactivation of all of the currently known
ligands in the B7-CD28/CTLA-4 pathway. In this report, B7-2 (Figures 1A±1C). This strategy was based on stud-
ies of B7-1 indicating that the IgV-like domain is criticalwe present the initial characterization of B7-22/2 and
B7-1/22/2 mice and compare the role of the B7 costimu- for costimulatory activity (Freeman et al., 1993a; Peach
et al., 1995). Germline transmitting chimeric mice gener-latory molecules in humoral immune responses. In vivo
immunization studies revealedan important role for B7-2 ated from targeted ES cells were bred to 129/SvJae
mice, and progeny heterozygous for the B7-2 mutationin immunoglobulin class switching and germinal center
formation, since B7-2-deficient mice displayed a com- were interbred. Genotyping of progeny resulting from
an intercross yielded the expected three types of prog-plete absence of isotype switching and germinal center
formation when immunized with antigen intravenously. eny as determined by Southern blot analysis (Figure 1D).
Because the murine B7-1 (mB7-1) and mB7-2 genesHowever, when immunized by other routes or with adju-
vant, B7-22/2 mice gave antigen-specific immunoglobu- are closely linked on mouse chromosome 16 (C. Dis-
teche and S. Edelhoff, personal communication), welin G (IgG) responses comparable with wild-type mice.
B7-12/2 gave antigen-specific IgG responses compara- could not interbreed the B7-12/2 and B7-22/2 strains to
generate a mouse strain lacking both B7-1 and B7-2.ble with wild-type mice irrespective of adjuvant or immu-
nization route. Mice lacking both B7-1 and B7-2, in con- To generate B7-1/22/2 mice, we used a B7-2 targeting
vector to retarget a J1 ES cell clone (E151) that carriedtrast, failed to generate an antigen-specific IgG1 or
B7-Deficient Mice
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Figure 2. Generation of Mice Lacking both
B7-1 and B7-2
(A) Structure of the B7-2 targeting construct.
The hygromycin resistance gene (hygR) is
flanked by z1.7 and z6.5 kb genomic DNA
fragments. The thymidine kinase gene (TK)
lies external to the 59 genomic DNA fragment.
The EcoRV and HindIII sites shown are the
sites used to generate the construct and to
analyze the integration sites. There are addi-
tional EcoRV and HindIII sites 39 of the hyg R
gene in the construct.
(B) Wild-type allele. Intron-exon organization
of the IgV-like, IgC-like, and transmembrane
domains of B7-2 are depicted as rectangles.
The genomic probe used for subsequent
Southern blotting is indicated with a closed
bar and is located external to the genomic
DNA fragment used in the targeting con-
struct.
(C) Structure of the predicted targeted allele.
Gene targeting in ES cells by homologous
recombination results in the replacement of
the IgV domain contained in a 0.9 kb HindIII±
EcoRI fragment with the hygromycin resis-
tance gene. Southern blot analysis uses the acquisition of an additional EcoRV site upstream of one already present in the IgC-like domain
to distinguish the targeted from the endogeneous allele.
(D) Southern blot analysis of tail DNA from B7-1/2 knockout (2/2), heterozygote (1/2), and wild-type (1/1) littermates demonstrating the
two bands indicative of the endogenous (8.5 kb) and targeted (8.0 kb) configurations.
the B7-1 deletion and was known to give germline trans- B7-1/22/2 mice. B7-2 expression was only observed in
wild-type cells, confirming a lack of expression in themission with an extremely high frequency (Freeman et
al., 1993a). The targeting vector carried a hygromycin B7-2 (Figure 3) and B7-1/22/2 mice (Figure 4). LPS±
dextran sulfate-stimulated B7-22/2 B cells expressedresistance gene as a positive selection marker because
the E151 clone was neomycin resistant (Figure 2A). Es-
sentially, the targeting vector was identical to the tar-
geting vector used to generate the B7-22/2 mice with
the exception that the neomycin resistance gene (neoR)
had been replaced with a hygromycin resistance gene
(hygR). Five ES clones carrying the desired homologous
recombination event were injected into blastocysts, and
all gave rise to germline transmission. Because the E151
clone was heterozygous for the B7-1 deletion, the B7-2
homologous recombination event could have occurred
on the same allele of chromosome 16 as the B7-1 dele-
tion, or the opposite allele. The inheritance of the neoR
and hygR drug resistance genes by progeny served as
an indicator of the integration event. If the homologous
recombination event occurred on the same allele as the
B7-1 deletion, then both the hygR and neoR genes would
be inherited by the progeny. On the other hand, if the
homologous recombination event occurred on the op-
posite allele, then mice would inherit either the hygR or
the neoR gene. Analysis of the offspring revealed that in
four of five clones analyzed, B7-1 and B7-2 were deleted
on the same chromosome, i.e., the offspring carry both
the neoR and hygR genes. Interbreeding of these hetero-
zygotes gave rise to viable mice carrying both the B7-1
and B7-2 mutations with the expected frequency, as
Figure 3. Analysis of B7-1 and B7-2 Expression and CTLA-4Ig Bind-determined by Southern blot analysis.
ing in Activated B Cells from Wild-Type and B7-22/2 Mice
Purified B cells from wild-type (top) and B7-22/2 (bottom) mice wereExpression of B7-1, B7-2, and CTLA-4Ig Binding
stimulated with LPS±dextran sulfate for the indicated number ofin B7-22/2 and B7-1/22/2 Mice
days and stained with anti-B7-1, anti-B7-2, and mCTLA-4Ig as indi-The expression of B7-1, B7-2, and total CTLA-4Ig coun-
cated. Solid lines denote staining with anti-B7-1, anti-B7-2, or
terreceptors was examined at various times after lipo- mCTLA-4Ig, and broken lines denote staining with an isotype-
polysaccharide (LPS)±dextran stimulation of either puri- matched negative control antibody (hamster, rat, or mouse immuno-
globulin, respectively).fied B cells or splenocytes from wild-type, B7-22/2, and
Immunity
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Figure 4. Analysis of B7-1 and B7-2 Expression and CTLA-4Ig Bind-
ing in Activated Splenocytes from B7-1/2 Double Knockout Mice
Spleen cells from wild-type and B7-1/22/2 mice were stimulated
with LPS-dextran sulfate for 3 days and stained with with anti-
B7-1, anti-B7-2, or mCTLA-4Ig as indicated. Staining at 72 hr post-
stimulation is shown. Solid lines denote staining with anti-B7-1,
anti-B7-2, or mCTLA-4Ig, and broken lines denote staining with an
isotype-matched negative control antibody (hamster, rat, or mouse
immunoglobulin, respectively).
B7-1 with kinetics of expression comparable with wild-
type mice, indicating that previous expression of B7-2
is not necessary for expression of B7-1, and these cells
bound murine CTLA-4Ig (mCTLA-4Ig) with temporal ki-
Figure 5. Anti-TNP-Specific Serum Immunoglobulin Isotype Levelsnetics correlating with the late expression of B7-1 (Fig-
on Day 7 Postimmunization with Intravenous TNP-KLHure 3). LPS-dextran sulfate-stimulated B7-1/22/2 splen-
Mice were immunized intravenously with 100 mg of TNP-KLH inocytes did not express B7-1 or B7-2. mCTLA-4Ig
PBS without adjuvant. Sera were analyzed for anti-TNP-specific
binding was not observed on B7-1/22/2 splenocytes at immunoglobulins by ELISA. Panels from top to bottom indicate rela-
any time over 4 days of stimulation with LPS±dextran tive IgM, IgG1, and IgG2a levels, respectively. Two mice of each
sulfate (Figure 4; data not shown). type were used in each of six repetitions of this experiment, which
gave similar results.
Humoral Immune Responses of B7-1- and
B7-2-Deficient Mice Immunized with factor (GM-CSF) can up-regulate expression of B7-1
Antigen without Adjuvant and B7-2 on APCs (Larsen et al., 1994).
In unimmunized mice basal serum immunoglobulin lev- When immunized with TNP-KLH or TNP-OVA in saline
els (total immunoglobulin, IgM, IgG1, and IgG2a) were by the intravenous route, B7-22/2 mice produced re-
identical among wild-type, B7-12/2, and B7-22/2 mice duced levels of totalserum anti-TNP antibodies, as com-
(data not shown). In contrast, unimmunized B7-1/22/2 pared with wild-type mice (data not shown). Signifi-
mice exhibited a 3- to 5-fold reduction in total serum cantly, B7-22/2 mice exhibited a striking reduction of
immunoglobulin and IgG2a, a 5- to 10-fold reduction in TNP-specific IgG1 and IgG2a isotypes, producing less
IgG1, but 3- to 5-fold elevations in IgM and IgG3. Flow than 5% of wild-type levels (Figure 5). In contrast, anti-
cytometric analyses revealed comparable numbers and TNP isotypes (IgG1, IgG2a, and IgM) produced by B7-
maturation of thymocytes inwild-type, B7-12/2, B7-22/2, 12/2 mice were all slightly reduced, approximately 25%±
and B7-1/22/2 mice. Similarly, analyses of spleen and 50% of wild-type levels. These patterns of anti-TNP
lymph nodes from wild-type, B7-12/2, and B7-22/2 mice isotype production remained essentially unchanged for
revealed comparable numbers of B2201, CD31, CD41, 4 weeks postimmunization, when the experiment was
and CD81 populations. terminated.
To compare antigen-specific T-dependent immune To analyze further the consequences of a lack of B7-2
responses in B7-1- and B7-2-deficient mice, we immu- on humoral immune responses, spleens were harvested
nized wild-type, B7-12/2, and B7-22/2 mice with the from wild-type, B7-12/2, and B7-22/2 mice at 7 days
hapten-protein conjugates, 2,4,6-trinitrophenyl±keyhole postimmunization and examined histologically. There
limpet hemocyanin (TNP-KLH) or 2,4,6-trinitrophenyl± was a striking absence of germinal center formation
ovalbumin (TNP-OVA), and examined the induction of in B7-22/2 spleens, and scant TNP-specific antibody-
TNP-specific serum immunoglobulin isotypes in vivo. forming cells were observed (Figure 6). In contrast, well-
We initially immunized mice with antigen without adju- formed germinal centers were seen in both wild-type
vant, because adjuvants can increase local inflamma- and B7-12/2 spleens. When the frequency of TNP-spe-
tory cytokine expression (Brett et al., 1993; Liu and cific antibody-forming cells was enumerated by ELIS-
Janeway, 1991), which can up-regulate the expression POT assay, there was a 97% reduction in antibody-
of costimulatory molecules. In particular, interferon-g forming cells present in the B7-22/2 spleen as compared
with wild-type mice (Table 1).(IFNg) and granulocyte/macrophage colony-stimulating
B7-Deficient Mice
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Table 1. Frequency of TNP-Specific Antibody-Forming Cells in
B72/2 Mice
Wild Type B7-12/2 B7-22/2
1 2542 1305 58
2 1305 1470 48
3 1488 1485 59
Frequency of TNP-specific antibody-forming cells was evaluated 7
days after intravenous injection of TNP-KLH using ELISPOT assay
and 30 3 106 spleen cells per mouse.
B7-2 delayed the antibody response, greatly reducing
the initial antibody response. In contrast, when mice
were immunized subcutaneously with TNP-KLH with
alum, no differences in humoral responses between
wild-type and B7-2-deficient mice were observed even
at 1 week postimmunization (data not shown). In addi-
tion, when B7-22/2 mice were immunized in the presence
of CFA with TNP-KLH intraperitoneally or in the footpad,
no differences in humoral responses between wild-type
and B7-2-deficient mice were observed at 1 week post-
Figure 6. Histology of Spleens from Mice Immunized with Intrave- immunization (Figure 8). In B7-12/2 mice, anti-TNP IgG1
nous TNP-KLH in the Absence of Adjuvant
and IgG2a responses were comparable with wild-type
Shown are spleen sections stained with PNA (a, c, and e) to visualize mice following immunization with adjuvant regardlessgerminal centers and TNP-alkaline phosphatase (b, d, and f) to
of the route of immunization or adjuvant used (Figurevisualize anti-TNP antibody-producing B cells. Wild-type (a and b)
7; data not shown).and B7-12/2 (c and d) spleens demonstrate well-formed germinal
centers, with a large number of anti-TNP antibody±producing B
cells. In contrast, B7-22/2 spleens (e and f) show no germinal centers Immunization of B7-1/2-Deficient Mice
and few detectable anti-TNP antibody±producing B cells (original
with Antigen in Adjuvantmagnification, 503). Three mice of each type were used in each of
To determine whether the antibody responses elicitedthree repetitions of this experiment, which gave similar results.
in the B7-22/2 mice in the presence of adjuvant or by
the subcutaneous route were due to B7-1 or other co-
stimulatory molecules, we examined immune responsesTo examine whether the route of immunization influ-
enced the humoral responses of B7-22/2 mice immu- in B7-1/22/2 mice. When we immunized the B7-1/22/2
mice with TNP-KLH in phosphate-buffered saline (PBS)nized in the absence of adjuvant,we compared the intra-
venous with the subcutaneous routes. On day 7 subcutaneously, we found that there was profound im-
pairment of IgG class switching, with ,0.1% of wild-following intravenous immunization, there was an ap-
proximately 95% reduction in TNP-specific IgG1 and type levels of anti-TNP IgG1 and IgG2a produced (data
not shown). These results indicate that B7-1 costimula-IgG2a responses as compared with wild-type mice (Fig-
ure 5), whereas after subcutaneous immunization, the tion accounts for the IgG responses in the B7-22/2 mice
immunized subcutaneously with TNP-KLH in PBS.anti-TNP antibody response of B7-22/2 mice was com-
parable with wild-type mice (data not shown). Thus, B7-2 Even when we immunized the B7-1/22/2 mice with
TNP-KLH along with the potent adjuvant CFA either in-is critical for antigen-specific IgG1 and IgG2a production
following intravenous immunization, but not subcutane- traperitoneally or in the footpad, B7-1/22/2 mice pro-
duced reduced levels of totalserum anti-TNP antibodiesous immunization.
as compared with wild-type mice. Importantly, B7-1/
22/2 mice exhibited a striking reduction of anti-TNP IgG1Immunization of B7-1- or B7-2-Deficient
Mice with Antigen in Adjuvant and IgG2a isotypes, producing ,0.1% of wild-type lev-
els of anti-TNP IgG1 and usually less than 0.1% of wild-We next compared immunization of B7-deficient mice
in the presence of adjuvant. When mice were immunized type levels of anti-TNP IgG2a. However, we occasionally
observed up to 5% of wild-type levels of anti-TNP IgG2a.intraperitoneally with TNP-KLH or TNP-OVA in the pres-
ence of alum, there was a marked reduction in total The anti-TNP IgM response ranged from z10%±30% of
wild-type levels (Figure 8). These patterns of anti-TNPanti-TNP immunoglobulin production in B7-22/2 mice as
compared with wild-type mice at 1 week postimmuniza- specific isotype production remained essentially un-
changed for 4 weekspostimmunization, when theexper-tion. Anti-TNP IgM responses were reduced only 25%±
50% compared with wild-type, whereas both anti-TNP- iment was terminated.
To analyze further the consequences of a lack of bothspecific IgG1 and IgG2a were reduced by greater than
95% compared with the wild-type response (Figure 7, B7-1 and B7-2 on humoral immune responses, spleens
were harvested from wild-type, B7-22/2, and B7-1/22/2left column). This reduction in anti-TNP IgG responses
became less marked by 14 days postimmunization (data mice at 7±10 days postimmunization with CFA intraperi-
toneally and examined. B7-1/22/2 spleens were signifi-not shown) and altogether absent at 21 days postimmu-
nization (Figure 7, right column). Therefore, by the intra- cantly smaller than wild-type or B7-22/2 spleens. His-
tological examination revealed a virtually completeperitoneal route of immunization with alum, a lack of
Immunity
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Figure 7. Anti-TNP-Specific Serum Immuno-
globulin Isotype Levels on Days 7 and 21 after
Intraperitoneal Immunization with 100 mg of
TNP-KLH in PBS with Alum
Sera were analyzed for TNP-specific immu-
noglobulins by ELISA. Panels from top to bot-
tom indicate relative IgM, IgG1, and IgG2a
levels, respectively. Similar results were ob-
tained using two mice of each type in each
of three separate experiments.
absence of TNP-specific antibody-forming cells (Figure role than B7-1. B7-1/2-deficient mice exhibited a pro-
found deficit in isotype switching, accompanied by an9). The lymphoid follicles were small with no alteration
of the lymphoid architecture. They resembled primary absence of germinal center formation irrespective of
route of immunization or the presence of adjuvant. Thefollicles without recognizable germinal centers; all con-
tained B2201 cells (Figure 9). For the most part, however, lack of B7-1 and B7-2, however, did not markedly affect
antigen-specific IgM production, indicating that B cellpeanut agglutinin (PNA)1 staining was absent (Figure 9).
In occasional follicles, we observed faint staining with responsiveness is not dependent on B7 expression.
However, the class switch to IgG, which is dependentPNA in very small clustersof cells, which contrasted with
robust PNA1 clusters in the large, well-formed germinal upon the function of T helper cells through T±B inter-
actions, was markedly affected, suggesting that T cellcenters seen in both wild-type and B7-22/2 spleens.
Similar results were observed when draining lymph help is critically diminished by the absence of B7-1 and
B7-2.nodes of B7-1/22/2 were examined following footpad
immunization with TNP-KLH in CFA or using TNP-OVA Our in vivo immunization results are consistent with
studies examining the in vivo effects of anti-B7-2 MAbin CFA.
upon a primary response to the haptenated protein con-
jugate NP-CG administered intraperitoneally with alumDiscussion
(Han et al., 1995). In these studies, anti-B7-2 MAb ar-
rested germinal center formation and resulted in a 50%Signaling through the B7-CD28/CTLA-4 costimulatory
pathway is complex owing to the presence of multiple reduction in primary antibody production. Anti-B7-2
MAbmarkedly reduced somatic hypermutation in germi-receptors and ligands, together with the potential for
both positive and negative signaling. To dissect the in nal centers and altered the kinetics of antibody produc-
tion in the secondary response of mice treated withvivo functions of the B7 costimulatory molecules, we
have generated mice lacking expression of B7-1 or B7-2 anti-B7-2 MAb for 3 days during the primary response,
suggesting that B7-2 plays an important role in B cellor both B7 costimulatory molecules. These strains pro-
vide a means for comparing the in vivo function of these memory. Similarly, our results complement the finding
of a lack of germinal centers in CD282/2 mice (Fergusonimportant regulators of immune responses. In this re-
port, we present the initial characterization of the B7- et al., 1996).
The deficits in humoral immune responses observed22/2 and B7-1/22/2 strains and compare their immune
capabilities with previously described B7-1-deficient in the B72/2 mouse strains have implications for the
mechanism behind the immunopotentiating activity ofmice (Freeman et al., 1993a). The phenotypes of these
strains demonstrate important overlapping roles for adjuvants. For example, Neisserial porins, which are po-
tent adjuvants, can induce B lymphocytes to expressB7-1 and B7-2 in immunoglobulin class switching and
germinal center formation, with B7-2 having a greater B7-2 (Wetzler et al., 1996). Our studies suggest that the
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proaches may be a consequence of the important role
of the B7-CD28 pathway for immunoglobulin class
switching and germinal center formation.
We observed markedly different antibody responses
in B7-22/2 mice depending upon the immunization route
employed and the presence or absence of adjuvant.
B7-22/2 mice immunized intravenously without adjuvant
exhibited a complete lack of class switching and germi-
nal center formation. When immunized intraperitoneally
without adjuvant, they exhibited a delay in the kinetics
of the IgG responses, whereas when immunized subcu-
taneously, their IgG responses were comparable with
wild-type mice. Interestingly, studies by Jenkins and his
colleagues have indicated that the subcutaneous route
of immunization leads to a more vigorous inflammatory
response as compared with the intraperitoneal route
(Kearney et al., 1994). Immunization studies in B7-1/22/2
mice show that the presence of B7-1 in the B7-22/2
mouse provides the costimulation responsible for hu-
moral immune responses after immunization in the pres-
ence of adjuvant or by all immunization routes except
the intravenous route, where B7-2 is necessary and suf-
ficient for the humoral response. Local inflammatory
responses elicited by certain routes of immunization or
by adjuvants apparently stimulate up-regulation of B7-1.
For example, cytokines, including IL-4, tumor necrosis
factor a, IFN-g, and GM-CSF, can up-regulate B7-1 ex-
pression. In addition, different routes of immunization
or adjuvants may utilize distinct APC subpopulations,
in which the kinetics and regulation of B7-1 expression
Figure 8. Anti-TNP-Specific Serum Immunoglobulin Isotype Levels
may differ.on Day 7 Postimmunization in the Footpad with 100 mg of TNP-KLH
Recent studies comparing the costimulatory roles ofin CFA
B7-1 and B7-2 have suggested that B7-2 may have anSera were analyzed for TNP-specific immunoglobulins by ELISA.
important costimulatory role for Th2 responses. The re-Panels from top to bottom indicate relative IgM, IgG1, and IgG2a
duction of both IgG1 and IgG2a production in our immu-levels, respectively. Similar results were obtained using five mice
of each type in each of three separate experiments. nization studies in B7-22/2 mice indicates that B7-2 can
influence both Th1- and Th2-dependent responses in
vivo. However, while the deficits in both IgG1 and IgG2a
up-regulation of B7-1, B7-2, or both either directly or production are profound in the B7-1/22/2 strain, it is
indirectly by adjuvants would enhance T-B collabora- interesting to note that there was virtually no anti-TNP-
tions critical for immunoglobulin class switching and specific IgG1 response detectable, whereas the anti-
germinal center formation. Our findings further suggest TNP-specific IgG2a response was also markedly re-
duced ($95%), but still present. The influence of B7-1that the efficacy of B7 costimulation±based vaccine ap-
Figure 9. Histology of Spleens from Mice Im-
munized Intraperitoneally with TNP-KLH in
CFA
Shown are spleen sections stained with PNA
(a, b, and c) to visualize germinal centers and
TNP±alkaline phosphatase (d, e, and f) to vi-
sualize anti-TNP antibody±producing B cells.
Wild-type (a and d) and B7-22/2 (b and e)
spleens demonstrate well-formed germinal
centers, with a demonstrable large number
of anti-TNP antibody±producing B cells. In
contrast, B7-1/22/2 spleens (c and f) show no
germinal centers and no detectable anti-TNP
antibody±producing B cells (original magnifi-
cation, 503). The presence of B cells in B7-
1/22/2 spleens was confirmed using anti-
B220 (i). Three mice of each type were used
in eachof three repetitions of this experiment,
which gave similar results.
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and B7-2 on Th1 and Th2 responses is being addressed of B7-1 and B7-2 should enable more effective manipu-
lation of this critical costimulatory pathway for therapeu-more precisely using B7-deficient strains together with
tic purposes. In addition, the B7-1/22/2 strain also willTCR transgenic mice. In addition, we are currently in-
be an important tool for evaluating the relative contribu-vestigating the consequences of infecting B7-12/2 and
tion of other costimulatory pathways in T cell activation.B7-22/2 mice with Leishmania major and Schistosoma
mansoni, infections for which an in vivo role of the two
Experimental Proceduressubsets of T helper cells has been demonstrated (Sal-
game et al., 1991; Heinzel et al., 1989; Kawabe et al.,
Mice1994).
BALB/c and C57BL/6 mice were obtained from Taconic Laboratory.
The class switching defect in the B7-22/2 mice is simi- 129/SvJae mice were maintained in our breeding colony. All experi-
lar to the phenotype observed in both the CD40- and ments comparing wild-type, B7-1-, B7-2-, and B7-1/2-deficient mice
the CD40 ligand (CD40L)-deficient mice (Kawabe et al., used 129 inbred animals. Brigham and Women's Hospital and Har-
vard Medical School are AAALAC accredited institutions, and the1994; Xu et al., 1994). Previous studies have indi-
mice were cared for in accordance with institutional guidelines.cated an important interrelationship between the CD40-
CD40L and B7-CD28/CTLA-4 pathways. CD40-CD40L
Homologous Recombination Constructinteractions can result in the up-regulation of expression and Targeting of ES Cells
of B7-1 and B7-2 (Roy et al., 1995; Ranheim and Kipps, DNA encoding the mouse B7-2 gene was isolated from a 129 geno-
1995). Similarly, B7-1 and B7-2 binding to T cells can mic library as previously described (Borriello et al., 1995). The tar-
geting vector described in Figure 1A was constructed in pBluescriptresult in up-regulation of CD40L expression (de Boer et
KS(1) (Stratagene, La Jolla, CA) by replacing a 0.9 kb HindIII±EcoRIal., 1993). Our in vivo studies would suggest that signal-
fragment of the mB7-2 gene containing the IgV-like domain and theing through both pathways may be needed in order for
39 flanking intron with the neomycin drug resistance gene driven by
class switching to occur. Therefore, the deficit in both the mouse phosphoglycerol kinase (Pgk1) promoter (McBurney et
antigen-specific IgG1 and IgG2a responses in the B7- al., 1991) and linked to the Pgk1 poly(A)sequences. To select against
1/22/2 strain might be a consequence of impaired CD40L random insertional events, a thymidine kinase (TK) gene under the
regulation of the MC1 promoter was incorporated at the 59 end ofexpression or Th1 and Th2 cytokines, or both. Further
the targeting vector (Mansour et al., 1988). The recombination vectoranalyses of B7-deficient mice, as well as CD40- and
contained 1.7 kb (HindIII±EcoRI) and 6 kb (EcoRI fragment con-CD40L-deficient mice, together with an expanded analy-
taining the IgC-like and the transmembrane exons) of homology
sis of the cytokine profile in these animals, should lead upstream and downstream, respectively, of the Pgk±neoR gene and
to a better understanding of the mechanistic relationship the pMC thymidine kinase gene at its most 59 end. The vector was
between these pathways and class switching. linearized using a unique NotI site and transfected into the J1 ES
cell line. G418- and FIAU-resistant ES cell colonies were picked andMice lacking both B7-1 and B7-2 serve as definitive
expanded. DNA was prepared and analyzed by Southern blottingtools for determining whether additional CD28/CTLA-4
using DNA probes from outside the homologous recombination
counterreceptors exist and provide a means to assess area, as depicted in Figure 1. Genomic DNA was digested with
their functional importance. In this study, we evaluated EcoRV and hybridized with a 0.9 kb EcoRI fragment external and
B7-1/22/2 B cells for their capacity to bind murine CTLA- adjacent to the 1.7 kb 59 homology segment used in the targeting
construct. A DNA restriction fragment of 8.5 kb corresponded to4Ig and did not observe mCTLA-4Ig binding on resting
the wild-type allele and 7.0 kb restriction fragment resulted fromor stimulated B7-1/22/2 B cells. Further studies are
the targeted allele. Single integration events were scored using aneeded to evaluate B cells stimulated by other methods
probe derived from the neoR gene. Two distinct ES cell lines hetero-
and other APC populations for additional CD28/CTLA-4 zygous for the mutation were microinjected into blastocysts from
counterreceptors. Our findings suggest that if additional C57BL/6 and BALB/c mice and gave rise to germline transmission
of the B7-2 mutation. Mice heterozygous for the mutant mB7-2 alleleCD28/CTLA-4 counterreceptors exist, then they have a
were interbred, and the genotype of progeny was determined bymuch more restricted pattern of expression than B7-1
Southern blot analysis of tail DNA. The results reported here haveand B7-2, or have only a low affinity for CTLA-4. The
been observed with two independent clones that gave germline
profound deficits observed in B7-1/22/2 mice, however, transmission.
also suggest that if additional CD28/CTLA-4 counterre- To generate B7-1/22/2 mice, we used a modified B7-2 targeting
ceptors exist, they either do not stimulate T cell activa- vector to retarget a J1 ES cell clone (E151) that was heterozygous
for the B7-1 mutation and was known to give germline transmissiontion or only function to activate T cells in a restricted
with an extremely high frequency (Freeman et al., 1993a). The closemicroenvironment.
genetic linkage of B7-1 and B7-2 necessitated this retargeting ap-
This comparative analysis of B7-12/2, B7-22/2, and proach. Because the E151 clone was neomycin resistant, the tar-
B7-1/22/2 mice demonstrates significant differences in geting vector carried a hygromycin resistance gene as an alternative
the phenotypes of these strains. The distinct pheno- positive selection marker (Figure 2A). Essentially, the targeting vec-
tor was identical to the targeting vector used to generate the B7-types of B7-12/2 and B7-22/2 mice may be a conse-
22/2 mice with the exception that the neomycin resistance genequence of the distinct temporal expression patterns of
had been replaced with the hygromycin resistance gene (Gritz andB7-1 and B7-2, with the early expression of B7-2 leading
Davies, 1993; Kaster et al., 1993). The vector was linearized using
to an important role for B7-2 at the initiation of an im- a unique NotI site and transfected into the E151 ES cell line. Hygro-
mune response. In addition, it may be that B7-1 and mycin- and FIAU-resistant ES cell colonies were picked and ex-
panded on irradiated hygromycin-resistant embryonic fibroblastsB7-2 can interact in distinct ways with their receptors,
(Johnson et al., 1995). DNA was prepared and analyzed by SouthernCD28 and CTLA-4. Further analyses of mice lacking
blotting using DNAprobes from outside the homologous recombina-B7-1, B7-2, or both should lead to a better understand-
tion area, as depicted in Figure 2. Genomic DNA was digested with
ing of the role of B7-1 and B7-2 in immune responses EcoRV and hybridized with a 0.9 kb EcoRI fragment external and
to infectious agents and tumors, in transplant rejection, adjacent to the 1.7 kb 59 homology segment used in the targeting
construct. A DNA restriction fragment of 8.5 kb corresponded toand in autoimmunity. Elucidating the in vivo functions
B7-Deficient Mice
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the wild-type allele and 8.0 kb restriction fragment resulted from plates coated with TNP±bovine serum albumin (TNP-BSA) and iso-
type-specific alkaline phosphatase±conjugated developing re-the targeted allele. Single integration events were scored using a
probe derived from the hygR gene. Five distinct ES cell lines hetero- agents as previously described (Burstein et al., 1991). Results are
expressed as OD405 absorbance values.zygous for the mutation were microinjected into blastocysts from
C57BL/6 and BALB/c mice and gave rise to germline transmission
of the B7-2 mutation. Because the E151 clone was heterozygous ELISPOT Assay
for the B7-1 deletion, the probability of a B7-2 homologous recombi- Serial dilutions of spleen cells from each mouse were performed
nation event on the same allele of chromosome 16 as the B7-1 in 24-well plates previously coated with TNP-BSA (50 mg/ml) and
deletion was 50%. Using the neoR and hygR drug resistance genes subsequently blocked with BSA. Following a 4 hr incubation at 378C
as markers of the individual recombination events, we selected for in completeculture media, wells were washed with PBS, 0.1% Triton
progeny in which these markers cosegregated. This indicated that X-100 and then incubated for 1 hr with PBS, 0.1% Triton X-100
the neoR and hygR genes were on the same chromosome, whereas containing 1:1000 alkaline phosphatase±conjugated goat anti±
they would have been inherited individually if they had been on mouse IgM (Southern Biotechnology Associates Inc., Birmingham,
different alleles. Offspring carrying both the neoR and hygR genes AL) at 378C. After several washes with PBS, 0.1% Triton X-100, 500
were identified by Southern blot analysis using neoR andhygR probes ml of a hot (568C) 1:4 mix of agarose in distilled water containing
shown in Figures 1 and 2. These heterozygotes were interbred, and BCIP (1.25 mg/ml) in AMP buffer (1 M 2-amino-2-methyl-L-propanol
the genotype of progeny was determined by Southern blot analysis [pH 10.25], containing 1 mM MgCl2, 0.01% Triton X-405, 0.1% so-
of tail DNA. The results reported here have been observed with two dium azide) was added to each well. Solidification of this substrate
independent clones that gave germline transmission. solution prevented diffusion of the reaction product, permitting as-
sessment of the frequency of TNP-specific antibody-forming cells
by counting the number of blue ªdotsº in the culture wells.
Cell Preparations and Cultures
Cell suspensions from thymus, spleen, and lymph nodes were pre-
Histochemical Staining for TNP-Specific B Cellspared by grinding tissue through sterile wire mesh. To isolate small
The TNP-alkaline phosphatase conjugate (TNP-AP) was preparedresting B cells, splenocytes were depleted of T cells by treatment
by the method of Claassen and Van Rooijen (1984). TNP-specific Bwith an antibody cocktail made up of anti-CD4 (GK1.5), anti-CD8
cells were visualized by incubating acetone-fixed frozen sections(ADH4), and anti-Thy1.2. Cells surviving the complement lysis were
with TNP-AP (4 U/ml) in the dark, followed by incubation with BCIP/placed on a Percoll step gradient and the small resting lymphocytes
NBT in the presence of levamisol. A bright blue reaction productrecovered from the 65%/72% interface.
appeared over TNP-specific B cells. Slides were washed in distilled
water and then mounted using an aqueous mounting media (Crystal/
Cell Surface Staining Mount; Biomeda Corp., Foster City, CA) without counterstain. Ger-
Thymus, spleen, and lymph node cells were stained with a panel of minal centers were visualized by PNA-peroxidase staining (Rose et
fluorochrome-conjugated antibodies, including fluorescein isothio- al., 1980). B cells were visualized by incubating tissue sections
cyanate±conjugated and phycoerythrin-conjugated anti-CD3, anti- with biotinylated anti-B220 (Pharmingen) and streptavidin alkaline
B220, anti-CD4, and anti-CD8 (Pharmingen, San Diego, CA). Cells phosphatase (Jackson Immunoresearch, West Grove, PA), as de-
(5 3 103) with the forward and side scatter properties of lymphocytes scribed. Diaminobenzidine was used as the chromagen.
were analyzed for each sample. All of these antibodies were pur-
chased from Pharmingen. Acknowledgments
To assay expression of B7-1 or B7-2 or CTLA-4Ig binding, we
stimulated either small restingB cells (2 3 106 per milliliter) orspleno- Correspondence should be addressed to A. H. S. We thank L. Du
cytes with LPS (Sigma, St. Louis, MO) (20 mg/ml) and dextran sulfate for expert technical assistance with blastocyst injections, C. P. Ler-
(10 mg/ml). At 0, 24, and 72 hr cells were stained with anti-B7-1 (16- ner and K. A. Johnson for assistance with hygromycin mouse devel-
10A1) (Reiser et al., 1992), anti-B7-2 (GL-1) (Hathcock et al., 1993) opment, B. Chang for assistance with mouse strain maintenance,
or murine CTLA-4Ig (Steurer et al., 1995), as previously described. and A. Abbas and L. Nadler for thoughtful comments on the manu-
Stained cells were analyzed on a FACSTAR plus (Becton Dickinson, script. We thank Hans Reiser for the anti-mB7-1 MAb (16-10A1)
Mountain View, CA). and Richard Hodes for the anti-mB7-2 MAb (GL-1). This work was
supported by a grant from the Lucille P. Markey Foundation (to
A. H. S.), the American Cancer Society (to A. H. S. and G. J. F.),Immunization of Mice
National Institutes of Health (NIH) awards PO1 AI35225 andWild-type 129/SvJae mice, B7-1, B7-2, and B7-1/2 deficient mice
1P30AR42689 (to A. H. S.), NIH training grant T32 HLO7627 (to E.(8±12 weeks old) were immunized with 100 mg of TNP-KLH or TNP-
A. T.), NIH grant R01 AI37798 (to T. B. S.), Cancer Research InstituteOVA in PBS either intravenously via the tail vein or subcutaneously
Fellowship (to F. B.), NIH grant K08AI01372-01 (to M. P. S.), Nationalvia a site on the back, or in alum (Pierce, Rockford, Illinois) as an
Science Foundation grant MCB-9513537 (to E. M. S.), and NIH Can-adjuvant either intraperitoneally or subcutaneously, or in CFA (Difco,
cer Core Center grant CA34196 (to the Jackson Laboratory).Detroit, Michigan) intraperitoneally or in the footpad. Animals were
bled for serum on the day prior to immunization and at days 7,
Received July 1, 1996; revised January 13, 1997.14, 21, and 28 postimmunization. TNP-specific titers of sera were
measured as described below. The hapten TNP (Sigma) was conju-
Referencesgated to KLH or OVA (Calbiochem, La Jolla, CA) as described by
Burstein et al. (1991).
Azuma, M., Ito, D., Yagita, H., Okumura, K., Phillips, J.H., Lanier,
L.L., and Somoza, C. (1993). B70 antigen is a second ligand for
Antibody Assays CTLA-4 and CD28. Nature 366, 76±79.
Immunoglobulin levels in sera were assayedby solid-phaseenzyme- Boom, W.H., Liano, D., and Abbas, A.K. (1988). Heterogeneity of
linked immunosorbent assay (ELISA) using goat anti±mouse immu- helper/inducer T lymphocytes. II. Effects of IL-4 and IL-2 producing
noglobulin antibody±coated plates and alkaline phosphatase± T cell clones on restingB lymphocytes. J. Exp. Med. 167, 1350±1363.
conjugated isotype-specific anti-immunoglobulin antibodies as
Borriello, F., Oliveros, J., Freeman, G.J., Nadler, L.M., and Sharpe,developing reagents, as previously described (Boom et al., 1988).
A.H. (1995). Differential expression of alternate mB7-2 transcripts.Sera were assayed at dilutions from 1:100 to 1:72,900, and immuno-
J. Immunol. 155, 5490±5497.globulin isotype concentrations were calculated from standard
curves generated with myeloma proteins. Boussiotis, V.A., Freeman, G.J., Gribben, J.G., Daley, J., Gray, G.,
and Nadler, L.M. (1993). Activated human B lymphocytes expressAnti-TNP antibody levels were determined by ELISA of serial dilu-
tions of sera. Titers of total mouse immunoglobulin, as well as iso- three CTLA-4 binding counter-receptors which costimulate T cell
activation. Proc. Natl. Acad. Sci. USA 90, 11059±11063.type-specific anti-TNP immunoglobulins, were measured using
Immunity
312
Brett, S.J., Dunlop, L., Liew, F.Y., and Tite, J.P. (1993). Influence of Gritz, L., and Davies, J. (1993). Plasmid-encoded hygromycin B re-
sistance: the sequence of the hygromycin B phosphotransferasethe antigen delivery system on immunoglobulin isotype selection
and cytokine production in response to influenza A nucleoprotein. gene and its expression in Escherichia coli and Saccharomyces
cerevisiae. Gene 25, 179±188.Immunology 80, 306±312.
Burstein, H.J., Tepper, R.I., Leder, P., and Abbas, A.K. (1991). Hu- Han, S., Hathcock, K., Zheng, B., Kepler, T.B., Hodes, R., and Kelsoe,
G. (1995). Cellular interaction in germinal centers: roles of CD40moral immune functions in IL-4 transgenic mice. J. Immunol. 147,
2950±2956. ligand and B7-2 in established germinal centers. J. Immunol. 155,
556±567.Claassen, E., and Van Rooijen, N. (1984). TNP-enzyme conjugates
for the detection of anti-TNP antibody producing cells in vivo. J. Harper, K., Balzano, C., Rouvier, E., Mattei, M.G., Luciani, M.F.,
and Golstein, P. (1991). CTLA-4 and CD28 activated lymphocyteImmunol. Meth. 75, 181±188.
molecules are closely related in both mouse and human as to se-Cross, A.H., Girard, T.J., Giacoletto, K.S., Evans, R.J., Keeling, R.M.,
quence, message expression, gene structure, and chromosomalLin, R.F., Trotter, J.L., and Karr, R.W. (1995). Long-term inhibition
location. J. Immunol. 147, 1037±1044.of murine experimental autoimmune encephalomyelitis using CTLA-
4-Fc supports a key role for CD28 costimulation. J. Clin. Invest. 95, Hathcock, K.S., Laszlo, G., Dickler, H.B., Bradshaw, J., Linsley, P.,
and Hodes, R.J. (1993). Identification of a novel CTLA-4 ligand that2783±2789.
is costimulatory for T cell activation. Science 262, 905±907.de Boer, M., Kasran, A., Kwekkeboom, J., Walter, H., Vandenberghe,
P., and Ceuppens, J.L. (1993). Ligation of B7 with CD28/CTLA-4 on Heinzel, F., Sadick, M., Holaday, B., Coffman, R.L., and Locksley,
R.M. (1989). Reciprocal expression of interferon g or interleukin 4T cells results in CD40 ligand expression, interleukin-4 secretion
and efficient help for antibody productionby B cells. Eur. J. Immunol. during the resolution or progression of murine leishmaniasis: evi-
dence for expansion of distinct helper T cell subsets. J. Exp. Med.23, 3120±3125.
169, 59±72.Ferguson, S.E., Han, S.H., Kelsoe, G., and Thompson, C.B. (1996).
CD28 is required for germinal center formation. J. Immunol. 156, Inaba, K., Witmerpack, M., Inaba, M., Hathcock, K.S., Sakuta, H.,
Azuma, M., Yagita, H., Okumura, K., Linsley, P.S., Ikehara, S., Mura-4576±4581.
matsu, S., Hodes, R.J., and Steinman, R.M. (1994). The tissue distri-Finck, B., Linsley, P., and Wofsy, D. (1994). Treatment of murine
bution of the B7-2 costimulator in mice: abundant expression onlupus with CTLA-4Ig. Science 265, 1225±1227.
dendritic cells in situ and during maturation in vitro. J. Exp. Med.
Freedman, A.S., Freeman, G.J., Horowitz, J.C., Daley, J., and Nadler, 180, 1849±1860.
L.M. (1987). B7, a B cell restricted antigen which identifies pre-
Johnson, K.A., Lerner, C.P., Di Lacio, L.C., Laird, P.W., Sharpe, A.H.,activated B cells. J. Immunol. 137, 3260±3267.
and Simpson, E.A. (1995). Transgenic mice for the preparation of
Freedman, A.S., Freeman, G.J., Rhynhart, K., and Nadler, L.M. hygromycin-resistant primary embryonic fibroblast feeder layers for
(1991). Selective induction of B7/BB-1 on interferon-g stimulated embryonic stem cell selections. Nucl. Acids Res. 23, 1273±1275.
monocytes: a potential mechanism for amplification of T cell activa-
June, C.H., Bluestone, J.A., Nadler, L.M., and Thompson, C.B.tion. Cell. Immunol. 137, 429±437.
(1994). The B7 and CD28 receptor families. Immunol. Today 15,
Freeman, G.J., Freedman, A.S., Segil, J.M., Lee, G., Whitman, J.F., 321±331.
and Nadler, L.M. (1989). B7, a new member of the Ig superfamily
Kaster, K.R., Burgett, S.G., Rao, R.N., and Ingolia, T.D. (1993). Analy-with unique expression on activated and neoplastic B cells. J. Immu-
sis of a bacterial hygromycin B resistance gene by transcriptionalnol. 143, 2714±2722.
and translational fusions and by DNA sequencing. Nucl. Acids Res.
Freeman, G.J., Gray, G.S., Gimmi, C.D., Lombard, D.B., Zhou, L.J., 11, 6895±6911.
White, M., Fingeroth, J.D., Gribben, J.G., and Nadler, L.M. (1991).
Kawabe, T., Naka, T., Yoshida, K., Tanaka, T., Fujiwara, H.,Structure, expression, and T cell costimulatory activity of the murine
Suematsu, S., Yoshida, N., Kishimoto, T., and Kikutani, H. (1994).homologue of the human B lymphocyte activation antigen B7. J.
The immune responses in CD40-deficient mice: impaired immuno-Exp. Med. 174, 625±631.
globulin class switching and germinal center formation. Immunity
Freeman, G.J., Borriello, F., Hodes, R.J., Reiser, H., Hathcock, K.S., 1, 167±178.
Laszlo, G., McKnight, A.J., Kim, J.L.D., Lombard, D.B., Gray, G.S.,
Kearney, E., Pape, K., Loh, D., and Jenkins, M. (1994). VisualizationNadler, L.M., and Sharpe, A.H. (1993a). Uncovering of functional
of peptide-specific T cell immunity and peripheral tolerance induc-alternative CTLA-4 counter-receptor in B7-deficient mice. Science
tion in vivo. Immunity 1, 327±339.262, 907±909.
Krummel, M.,and Allison, J.P. (1995). CD28 and CTLA-4 have oppos-Freeman, G.J., Borriello, F., Hodes, R.J., Reiser, H., Gribben, J.J.,
ing effects on the response of T cells to stimulation. J. Exp. Med.Ng, J.W., Kim, J., Goldberg, J.M., Hathcock, K.G.L., Lombard, L.A.,
182, 459±466.Wang, S., Gray, G., Nadler, L.M., and Sharpe, A.H. (1993b). Murine
B7-2, an alternative CTLA-4 counter-receptor that costimulates T Lanier, L.L., Ofallon, S., Somoza, C., Phillips, J.H., Linsley, P., Oku-
mura, K., Ito, D., and Azuma, M. (1995). CD80 (B7) and CD86(B70)cell proliferation and interleukin-2 production. J. Exp. Med. 178,
2185±2192. provide similar costimulatory signals for T cell proliferation, cytokine
production, and generation of CTL. J. Immunol. 154, 97±105.Freeman, G.J., Gribben, J.G., Boussiotis, V.A., Ng, J.W., Restivo, V.,
Lombard, L., Gray, G.S., and Nadler, L.M. (1993c). Cloning of B7-2: Larsen, C.P., Ritchie, S.C., Hendrix, R., Linsley, P.S., Hathcock, K.S.,
Hodes, R.J., Lowry, R.P., and Pearson, T.C. (1994). Regulation ofa CTLA-4 counter-receptor that costimulates human T cell prolifera-
tion. Science 262, 909±911. immunostimulatory function and costimulatory molecule (B7-1 and
B7-2) expression on murine dendritic cells. J. Immunol. 152, 5208±Freeman, G.J., Boussiotis, V.A., Anumanthan, A., Bernstein, G.M.,
5219.Ke, X.Y., Rennert, P.D., Gray, G.S., Gribben, J.G., and Nadler, L.M.
(1995). B7-1 and B7-2 do not deliver identical costimulatory signals, Lenschow, D.J., Zeng, Y., Thistlethwaite, J.R., Montag, A., Brady,
W., Gibson, M.G., Linsley, P.S., and Bluestone, J.A. (1992). Long-since B7-2 but not B7-1 preferentially costimulates the initial pro-
duction of IL-4. Immunity 2, 523±532. term survival of xenogeneic pancreatic islet grafts induced by CTLA-
4Ig. Science 257, 789±792.Gajewski, T.F. (1996). B7-1 but not B7-2 efficiently costimulates
CD81 T lymphocytes in the P815 tumor system in vitro. J. Immunol. Lenschow, D.J., Sperling, A.I., Cooke, M.P., Freeman, G., Rhee, L.,
Decker, D.C., Gray, G., Nadler, L.M., Goodnow, C.C., and Bluestone,156, 465±472.
J.A. (1994). Differential upregulation of the B7-1 and B7-2 costimula-Gribben, J.G., Freeman, G.J., Boussiotis, V.A., Rennert, P., Jellis,
tory molecules following immunoglobulin receptor engagement byC.L., Greenfield, E., Barber, M., Gray, G.S., and Nadler, L.M. (1994).
antigen. J. Immunol. 153, 1990±1997.CTLA-4 mediated costimulation induces apoptosis of activated hu-
man T lymphocytes. Proc. Natl. Acad. Sci. USA 92, 811±815. Lenschow, D.J., Ho, S.C., Sattar, H., Rhee, L., Gray, G., Nabavi, N.,
B7-Deficient Mice
313
Herold, K.C., and Bluestone, J.A. (1995). Differential effects of anti- Waterhouse, P., Penninger, J.M., Timms, E., Wakeham, A., Shahi-
nian, A., Lee, K.P., Thompson, C.B., Griesser, H., and Mak, T. (1995).B7-1 and anti-B7-2 monoclonal antibody treatment on the develop-
ment of diabetes in the nonobese diabetic mouse. J. Exp. Med. 181, Lymphoproliferative disorders with early lethality in mice deficient
in CTLA-4. Science 270, 985±988.1145±1155.
Wetzler, L.W., Ho, Y., and Reiser, H. (1996). Neisserial porins induceLinsley, P.S., Clark, E.A., and Ledbetter, J.A. (1990). T-cell antigen
B lymphocytes to express costimulatory B7-2 molecules and prolif-CD28 mediates adhesion with B cells by interacting with activation
erate. J. Exp. Med. 183, 1151±1159.antigen B7/BB-1. Proc. Natl. Acad. Sci. USA 87, 5031±5035.
Xu, J.C., Foy, T.M., Laman, J.D., Elliott, E.A., Dunn, J.J., Wald-Linsley, P.S., Greene, J.L., Brady, W., Bayorath, J., Ledbetter, J.A.,
schmidt, T.J., Elsemore, J., Noelle, R.J., and Flavell, R.A. (1994).and Peach, R. (1994). Human B7-1 (CD80) and B7-2 (CD86) bind with
Mice deficient for CD40 ligand. Immunity 1, 423±431.similar avidities but distinct kinetics to CD28 and CTLA-4 receptors.
Immunity 1, 793±801. Yokochi, T., Holly, R.D., and Clark, E.A. (1982). Lymphoblastoid anti-
gen (BB-1) expressed on Epstein-Barr virus-activated B cell blasts,Liu, Y., and Janeway, C.A. (1991). Microbial induction of co-stimula-
B lymphoblastoid lines, and Burkitt's lymphomas. J. Immunol. 128,tory activity for CD4 T cell growth. Int. Immunol. 3, 323±332.
823±827.Mansour, S.L., Thomas, K.R., and Capecchi, M.R. (1988). Disruption
of the protooncogene int-2 in mouse embryo-derived stem cells: a
general strategy for targeting mutations to non-selectable genes.
Nature 336, 348±352.
McBurney, M.W., Sutherland, L.C., Adra, C.N., Leclair, B., Rudnicki,
M.A., and Jardine, K. (1991). The mouse Pgk-1 gene promoter con-
tains an upstream activator sequence. Nucl. Acids Res. 19, 5755±
5761.
Miller, S., and Karpus, W. (1994). The immunopathogenesis and
regulation of T cell mediated demyelinating diseases. Immunol. To-
day 15, 356±361.
Peach, R.J., Bajorath, J., Naemura, J., Leytze, G., Greene, J., Aruffo,
A., and Linsley, P.S. (1995). Both extracellular immunoglobulin-like
domains of CD80 contain residues critical for binding T cell surface
receptors CTLA-4 and CD28. J. Biol. Chem. 270, 21181±21187.
Perrin, P.J., Scott, D., Quigley, L., Albert, P.S., Feder, O., Gray, G.S.,
Abe, R., June,C.H., and Racke, M.K. (1995). Roleof B7/CD28 CTLA-4
in the induction of chronic relapsing experimental allergic encepha-
lomyelitis. J. Immunol. 154, 1481±1490.
Ranheim, E.A., and Kipps, T.J. (1995). Tumor necrosis factor-a facili-
tates induction of CD80 (B7-1) and CD54 on human B cells by
activated T cells: complex regulation by IL-4, IL-10 and CD40L. Cell.
Immunol. 161, 226±235.
Reiser, H., Freeman, G.J., Razi-Wolf, Z., Gimmi, C.D., Benacerraf,
B., and Nadler, L.M. (1992). Murine B7 antigen provides an efficient
costimulatory signal for activation of murine T lymphocytes via the
T-cell receptor/CD3 complex. Proc. Natl. Acad. Sci. USA 89,
271±275.
Rose, M.L., Birbeck, M.S.C., Wallis, J.A., Forrester, J.A., and Davies,
A.J.S. (1980). Peanut lectin binding properties of germinal centres
of mouse lymphoid tissue. Nature 284, 364±366.
Roy, M., Aruffo, A., Ledbetter, J., Linsley, P., Kehry, M., and Noelle,
R. (1995). Studies on the interdependence of gp39 and B7 expres-
sion and function during antigen-specific immune responses. Eur.
J. Immunol. 25, 596±603.
Salgame, P., Abrams, J., Clayberger, C., Goldstein, H., Convit, J.,
Modlin, R.L., and Bloom, B.R. (1991). Differing lymphokine profiles
of functional subsets of human CD4 and CD8 cell clones. Science
254, 279±282.
Steurer, W., Nickerson, P., Stelle, A., Zheng, X., and Strom, B. (1995).
Ex vivo coating of islet cell allografts with murine CTLA-4/Fc pro-
motes graft tolerance. J. Immunol. 155, 1165±1174.
Tivol, E.A., Borriello, F., Schweitzer, A.N., Lynch, W.P., Bluestone,
J.A., and Sharpe, A.H. (1995). Loss of CTLA-4 leads to massive
lymphoproliferation and fatal multiorgan tissue destruction, reveal-
ing a critical negative regulatory role of CTLA-4. Immunity 3,
541±547.
Turka, L.A., Linsley, P.S., Lin, H., Brady, W., Leiden, J.M., Wei, R.Q.,
Gibson, M.L., Zheng, X.G., Myrdal, S., Gordon, D., Bailey, T., Bolling,
S.F., and Thompson, C.B. (1992). T-cell activation by the CD28ligand
B7 is required for cardiac allograft rejection in vivo. Proc. Natl. Acad.
Sci. USA 89, 11102±11105.
Walunas, T.L., Lenschow, D.J., Bakker, C.Y., Linsley, P.S., Freeman,
G.J., Green, M., Thompson, C.B., and Bluestone, J.A. (1994). CTLA-4
can function as a negative regulator of T cell activation. Immunity
1, 405±413.
